Drug makers and health insurers rose amid surprisingly strong earnings reports. Shire rose after the Irish drug maker, whose trans-Atlantic merger deal recently fell apart, boosted its profit outlook. Bristol Myers Squibb rose after the drug maker's quarterly sales and earnings exceeded Wall Street targets.

-Rob Curran, rob.curran@dowjones.com